Weiss Ratings Reaffirms "Sell (D-)" Rating for Oncology Institute (NASDAQ:TOI)

Key Points

• Weiss Ratings has reaffirmed a "Sell (D-)" rating for Oncology Institute (NASDAQ:TOI), indicating ongoing concerns about the stock's performance.
• Despite Weiss's rating, other firms like B. Riley and Noble Financial have issued "buy" and "outperform" ratings, with price targets of $6.00 and $8.00 respectively, reflecting a divergence in analyst opinions.
• Recent trading saw Oncology Institute's stock rise to $3.97, but it remains significantly below its one-year high of $4.50, with a market cap of $371.21 million and a P/E ratio of -5.84.

Oncology Institute (NASDAQ:TOI - Get Free Report)'s stock had its "sell (d-)" rating reiterated by Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

Several other research firms have also recently commented on TOI. B. Riley initiated coverage on shares of Oncology Institute in a research note on Wednesday, July 16th. They set a "buy" rating and a $6.00 target price on the stock. Noble Financial initiated coverage on shares of Oncology Institute in a research note on Wednesday, July 23rd. They issued an "outperform" rating and a $8.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $7.00.

Oncology Institute Stock Performance

Shares of Oncology Institute stock traded up $0.15 during trading hours on Wednesday, reaching $3.97. The company's stock had a trading volume of 1,371,747 shares, compared to its average volume of 1,673,166. The company has a debt-to-equity ratio of 14.58, a quick ratio of 1.37 and a current ratio of 1.62. Oncology Institute has a one year low of $0.13 and a one year high of $4.50. The company's 50 day simple moving average is $3.57 and its 200 day simple moving average is $2.90. The stock has a market cap of $371.21 million, a P/E ratio of -5.84 and a beta of 0.08.

Insiders Place Their Bets

In other news, Director Growth I. L.P. M33 sold 681,832 shares of the business's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $3.09, for a total value of $2,106,860.88. Following the sale, the director owned 590,892 shares in the company, valued at approximately $1,825,856.28. The trade was a 53.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 8.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in TOI. Josh Arnold Investment Consultant LLC acquired a new position in Oncology Institute during the 1st quarter worth about $2,267,000. Marshall Wace LLP acquired a new position in Oncology Institute during the 2nd quarter worth about $3,028,000. Geode Capital Management LLC lifted its position in Oncology Institute by 231.7% during the 2nd quarter. Geode Capital Management LLC now owns 1,279,443 shares of the company's stock worth $2,623,000 after buying an additional 893,696 shares in the last quarter. Tiff Advisory Services LLC lifted its position in Oncology Institute by 22.0% during the 2nd quarter. Tiff Advisory Services LLC now owns 3,634,465 shares of the company's stock worth $7,451,000 after buying an additional 655,324 shares in the last quarter. Finally, Balyasny Asset Management L.P. lifted its position in Oncology Institute by 17.3% during the 2nd quarter. Balyasny Asset Management L.P. now owns 2,518,337 shares of the company's stock worth $5,163,000 after buying an additional 371,005 shares in the last quarter. Institutional investors and hedge funds own 36.86% of the company's stock.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.